Faruqi & Faruqi Alerts Investors of Potential Class Action Against Marex Group plc

New York – On November 22, 2025, national securities law firm Faruqi & Faruqi, LLP announced an investigation into Marex Group plc (NASDAQ: MRX), giving shareholders who purchased or acquired the company’s securities between May 16, 2024 and August 5, 2025 the opportunity to seek appointment as lead plaintiff in a federal securities class action. According to the complaint, Marex and its executives allegedly violated federal securities laws by making false or misleading statements and/or omitting material facts. Among the claimed misrepresentations: the company purportedly sold over‑the‑counter financial instruments to itself; exhibited inconsistencies in its financial statements across subsidiaries and related parties (including intercompany receivables and loans); and consequently its financial statements were unreliable. As a result, defendants’ positive disclosures about Marex’s business, operations, and prospects were allegedly materially misleading. The investigation follows a report issued on August 5, 2025 by NINGI Research alleging a multi‑year accounting scheme at Marex, involving off‑balance‑sheet entities, fictitious transactions, and concealed losses—such as a $17 million fabricated receivable, inflated subsidiary profits, and nearly $1 billion in hidden derivatives exposure through a Luxembourg fund. The day the report was released, Marex’s stock dropped 6.2 %, closing at $35.31 on heavy volume. Investors wishing to discuss their legal rights can contact Faruqi & Faruqi partner James (Josh) Wilson at 212‑983‑9330 (Ext. 1310) or 877‑247‑4292. The deadline to seek appointment as lead plaintiff is December 8, 2025. #MarexGroup #SecuritiesClassAction #InvestorAlert #FaruqiFaruqi #SlimScan #GrowthStocks #CANSLIM